23511-05-9

Basic information

• Product Name: 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate
• Synonyms: 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate;1,4-Dioxaspiro[4.5]decan-8-yl 4-Methylbenzenesulfonate
• CAS NO: 23511-05-9
• Molecular Formula: C₁₅H₂₀O₅S
• Molecular Weight: 312.38
• Mol File: 23511-05-9.mol
• Article Data: 32

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate(23511-05-9)
• EPA Substance Registry System: 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate(23511-05-9)

Safety Data

• Hazardous Substances Data: 23511-05-9(Hazardous Substances Data)

Usage

General Description

1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate is a chemical compound that acts as a nucleotide analog. It is a derivative of the antiviral drug stavudine and is used in the treatment of HIV infection. 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate is a prodrug, meaning that it is converted into its active form in the body. Once activated, it inhibits the reverse transcriptase enzyme, which plays a crucial role in viral replication. This ultimately prevents the virus from multiplying and spreading within the body. Additionally, 1,4-Dioxaspiro[4.5]decan-8-ol 4-methylbenzenesulfonate has been studied for its potential use in combination therapy for HIV and other viral infections.

Upstream product

• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 104-15-4 toluene-4-sulfonic acid 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 23510-98-7 4-(methylthio)cyclohexan-1-one 
• 478364-11-3 4-[(1-phenylsulfonyl)ethyl]cyclohexan-1-one ethylene ketal 
• 478364-15-7 4-[(1-phenylsulfonyl)ethyl]cyclohexan-1-one 
• 55103-51-0 8-(methylthio)-1,4-dioxaspiro[4.5]decane 
• 1227611-94-0 4-(4-iodo-1H-pyrazol-1-yl)cyclohexanone 
• 1350324-96-7 trans-4-(4-{3-[(1S)-1-(2-chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3-methoxy-1H-pyrazol-1-yl)cyclohexanol 
• 1350325-01-7 trans-4-[4-(3-{(1S)-1-[2-chloro-6-(difluoromethoxy)-3-fluorophenyl]ethyl}-1H-pyrrolo[2,3-b]pyridin-5-yl)-3-methoxy-1H-pyrazol-1-yl]cyclohexanol 
• 1350322-63-2 trans-4-(4-{3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-3,5-dimethyl-1H-pyrazol-1-yl)cyclohexanol 
• 1350322-65-4 1-(trans-4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)-4-iodo-3,5-dimethyl-1H-pyrazole 
• 1350322-66-5 trans-4-(4-iodo-3,5-dimethyl-1H-pyrazol-1-yl)cyclohexanol 
• 1350324-98-9 1-(trans-4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)-4-iodo-3-methoxy-1H-pyrazole 
• 1350325-02-8 1-(trans-4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)-3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1350325-03-9 trans-4-(4-iodo-3-methoxy-1H-pyrazol-1-yl)cyclohexanol 
• 23511-04-8 4-oxocyclohexyl 4-methylbenzenesulfonate 

Relevant articles and documents

Electron Impact Mass Spectrometry of 3-Cyclohexen-1-ol and Related Compounds

The electron impact mass spectrum of 3-cyclohexen-1-ol has been studied, especially with regard to retro Diels-Alder reaction.Six deuterium labelled analogues and two dimethyl substituted homologues were synthesised.Contrary to what we have observed with 2-cyclohexen-1-ol, the double bond migration which precedes the retro Diels-Alder reaction plays a minor role.

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Stereospecific Nickel-Catalyzed Reductive Cross-Coupling of Alkyl Tosylate and Allyl Alcohol Electrophiles

The stereospecific cross-coupling of easily accessed electrophiles holds significant promise in the construction of C-C bonds. Herein, we report a nickel-catalyzed reductive coupling of allyl alcohols with chiral, nonracemic alkyl tosylates. This cross-coupling delivers valuable allylation products with high levels of stereospecificity across a range of substrates. The catalytic system consists of a simple nickel salt in conjunction with a commercially available reductant and importantly represents a rare example of a cross-coupling involving the C-O bonds of two electrophiles.